title: Guidelines for topical photodynamic therapy: update.
abstract: Multicentre randomized controlled studies now demonstrate high efficacy of topical photodynamic therapy (PDT) for actinic keratoses, Bowen's disease (BD) and superficial basal cell carcinoma (BCC), and efficacy in thin nodular BCC, while confirming the superiority of cosmetic outcome over standard therapies. Long-term follow-up studies are also now available, indicating that PDT has recurrence rates equivalent to other standard therapies in BD and superficial BCC, but with lower sustained efficacy than surgery in nodular BCC. In contrast, current evidence does not support the use of topical PDT for squamous cell carcinoma. PDT can reduce the number of new lesions developing in patients at high risk of skin cancer and may have a role as a preventive therapy. Case reports and small series attest to the potential of PDT in a wide range of inflammatory/infective dermatoses, although recent studies indicate insufficient evidence to support its use in psoriasis. There is an accumulating evidence base for the use of PDT in acne, while detailed study of an optimized protocol is still required. In addition to high-quality treatment site cosmesis, several studies observe improvements in aspects of photoageing. Management of treatment-related pain/discomfort is a challenge in a minority of patients, and the modality is otherwise well tolerated. Long-term studies provide reassurance over the safety of repeated use of PDT.
authors.affiliation: Department of Dermatology, Stirling Royal Infirmary, Stirling FK2 8AU, UK. colin.morton@nhs.net
authors.forename: C A
authors.initials: CA
authors.lastname: Morton
authors.forename: K E
authors.initials: KE
authors.lastname: McKenna
authors.forename: L E
authors.initials: LE
authors.lastname: Rhodes
mesh_terms: D000287:Administration, Topical; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D006801:Humans; D010778:Photochemotherapy / Q000009:adverse effects / Q000379:methods*; D017319:Photosensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D017319:Photosensitizing Agents